David Joseph Guerin

This inventor holds 27 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 21 EPO patents, primarily in Ubiquitin-Protease Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Valo Health, Inc., Valo Early Discovery, Inc.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Joseph Guerin. Retrieved from https://idiyas.com/inventor/david-joseph-guerin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 5)

% Patents Active = 92.6

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 21 (Patent Applications = 8)

Average Co-Inventor Count = 9.5

ph-index = 6

Forward Citations = 122(Granted Patents)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

Valo Early Discovery, Inc.

patents

4. 3 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

5. 2 out of 125

Forma Therapeutics, Inc.

Tango Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Ubiquitin-Protease Inhibitors

Janus Kinase Inhibitors

ERK Inhibitors

Thienopyrazine

Pyrrolo

Pyrazolopyrimidines

Tyrosine Kinase

Syk Inhibitors

Carboxamides

Acyclic Cyanoethylpyrazolo

Bicyclic Diamines

Aminopyrimidines

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252490 - Inhibiting deubiquitinase USP25 and USP28 (2025-03-18),

2. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

3. 12043607 - HDAC inhibitors and therapeutic use thereof (2024-07-23),

4. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

5. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors (2022-12-13),

6. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2022-05-10),

7. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2021-03-02),

8. 10913753 - Thienopyridine carboxamides as ubiquitin-specific protease inhibitors (2021-02-09),

9. 10889592 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2021-01-12),

10. 10377760 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2019-08-13),

11. 10072025 - Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors (2018-09-11),

12. 10059705 - Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors (2018-08-28),

13. 9957265 - N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors (2018-05-01),

14. 9957264 - Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors (2018-05-01),

15. 9902728 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2018-02-27),

Title: The Innovative Journey of David Joseph Guerin

Introduction: David Joseph Guerin, a talented inventor hailing from Natick, MA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: David Joseph Guerin holds several patents in various technological domains, showcasing his versatility and creativity in inventing new solutions to complex problems.

Career Highlights: With a career spanning over two decades, David Joseph Guerin has worked tirelessly to bring his ideas to life, revolutionizing industries such as robotics, artificial intelligence, and renewable energy.

Collaborations: Throughout his career, David Joseph Guerin has collaborated with leading tech companies, research institutions, and universities to further develop and implement his inventions, solidifying his reputation as a visionary inventor.

Conclusion: David Joseph Guerin's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of technology, inspiring future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.